Takeda Pharmaceutical Company Limited (FRA:TKD)

Avangrid Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	4,480,246	4,581,551	4,263,762	4,027,478	3,569,006	3,197,812
Revenue Growth (YoY)	1.52%	7.45%	5.87%	12.85%	11.61%	-2.84%
Cost of Revenue	1,569,140	1,571,419	1,431,505	1,253,163	1,127,308	1,013,655
Gross Profit	2,911,106	3,010,132	2,832,257	2,774,315	2,441,698	2,184,157
Selling, General & Admin	1,090,587	1,104,732	1,053,819	997,234	886,327	875,514
Research & Development	705,654	730,226	728,617	633,325	526,087	455,765
Other Operating Expenses	16,699	64,052	28,821	38,987	10,433	23,602
Operating Expenses	2,351,833	2,447,196	2,332,782	2,154,648	1,841,636	1,760,110
Operating Income	559,273	562,936	499,475	619,667	600,062	424,047
Interest Expense	-133,087	-130,487	-115,392	-116,973	-122,432	-130,806
Interest & Investment Income	63,064	19,983	11,628	5,781	4,763	2,153
Earnings From Equity Investments	-3,810	-3,986	6,473	-8,630	-15,367	76
Currency Exchange Gain (Loss)	786	786	-13,612	-9,729	-3,903	-15,575
Other Non Operating Income (Expenses)	-69,732	-24,865	-31,520	3,975	-26,119	1,118
EBT Excluding Unusual Items	416,494	424,367	357,052	494,091	437,004	281,013
Merger & Restructuring Charges	-128,133	-128,133	-81,358	-59,234	-83,836	-115,875
Gain (Loss) on Sale of Investments	-18,885	-18,885	-	22,416	8,482	-
Gain (Loss) on Sale of Assets	10,561	10,561	7,975	8,901	8,164	235,117
Asset Writedown	-81,479	-103,379	-146,047	-62,484	-54,421	-17,521
Legal Settlements	-	-	-45,212	-16,455	-20,319	-17,401
Other Unusual Items	-9,447	-9,447	-39,619	-12,145	7,497	902
Pretax Income	189,111	175,084	52,791	375,090	302,571	366,235
Income Tax Expense	51,988	66,941	-91,406	58,052	72,405	-9,936
Earnings From Continuing Operations	137,123	108,143	144,197	317,038	230,166	376,171
Minority Interest in Earnings	-200	-215	-130	-21	-107	-166
Net Income	136,923	107,928	144,067	317,017	230,059	376,005
Net Income to Common	136,923	107,928	144,067	317,017	230,059	376,005
Net Income Growth	-8.67%	-25.09%	-54.55%	37.80%	-38.81%	749.90%
Shares Outstanding (Basic)	1,578	1,579	1,564	1,552	1,564	1,562
Shares Outstanding (Diluted)	1,605	1,605	1,580	1,570	1,577	1,574
Shares Change (YoY)	1.18%	1.58%	0.67%	-0.46%	0.23%	0.47%
EPS (Basic)	86.78	68.36	92.09	204.29	147.14	240.72
EPS (Diluted)	85.30	67.23	91.16	201.94	145.87	238.96
EPS Growth	-9.74%	-26.25%	-54.86%	38.44%	-38.96%	745.88%
Free Cash Flow	911,034	856,387	540,924	836,499	999,853	899,725
Free Cash Flow Per Share	567.59	533.47	342.28	532.85	633.95	571.78
Dividend Per Share	196.000	196.000	188.000	180.000	180.000	180.000
Dividend Growth	4.25%	4.25%	4.44%	-	-	-
Gross Margin	64.98%	65.70%	66.43%	68.88%	68.41%	68.30%
Operating Margin	12.48%	12.29%	11.71%	15.39%	16.81%	13.26%
Profit Margin	3.06%	2.36%	3.38%	7.87%	6.45%	11.76%
Free Cash Flow Margin	20.33%	18.69%	12.69%	20.77%	28.02%	28.14%
EBITDA	1,219,015	1,233,262	1,143,936	1,284,067	1,183,213	983,718
EBITDA Margin	27.21%	26.92%	26.83%	31.88%	33.15%	30.76%
D&A For EBITDA	659,742	670,326	644,461	664,400	583,151	559,671
EBIT	559,273	562,936	499,475	619,667	600,062	424,047
EBIT Margin	12.48%	12.29%	11.71%	15.39%	16.81%	13.26%
Effective Tax Rate	27.49%	38.23%	-	15.48%	23.93%	-

Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.